Brain, Vol. 124, No. 7, 1426-1437,
July 2001
© 2001 Oxford University Press
Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjögren–Larsson syndrome
1 Departments of Paediatric Neurology, 2 Dermatology and 3 Laboratory of Paediatrics and Neurology, University Medical Centre, St Radboud, Nijmegen, Departments of 4 Clinical Biochemistry and 5 Paediatrics, Academic Medical Centre, University of Amsterdam, 6 Department of Neurology, Laurentius Hospital, Roermond, The Netherlands and 7 Division of Metabolic and Endocrine Diseases, University Children's Hospital, Heidelberg, Germany
Correspondence to:
M. A. A. P. Willemsen, Department of Paediatric Neurology, University Medical Centre St Radboud, PO Box 9101, 6500 HB Nijmegen, The Netherlands E-mail: m.willemsen{at}ckskg.azn.nl or R. J. A. Wanders, Departments of Paediatrics and Clinical Chemistry, Academic Medical Centre, University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, The Netherlands E-mail: wanders{at}amc.uva.nl
Sjögren–Larsson syndrome (SLS) is an autosomal recessively inherited neurocutaneous disorder caused by a deficiency of the microsomal enzyme fatty aldehyde dehydrogenase (FALDH). We report the clinical characteristics and the results of molecular studies in 19 SLS patients. Patients 1–17 show the classical triad of severe clinical abnormalities including ichthyosis, mental retardation and spasticity. Most patients were born preterm, and all patients exhibit ocular abnormalities and pruritus. Electro-encephalography shows a slow background activity, without other abnormalities. MRI of the brain shows an arrest of myelination, periventricular signal abnormalities of white matter and mild ventricular enlargement. Cerebral 1H-MR spectroscopy reveals a characteristic, abnormal lipid peak. The degree of white matter abnormality in the MRIs and the height of the lipid peak in 1H-MR spectra do not correlate with the severity of the neurological signs. The clinical presentation and the clinical course is strikingly similar in these patients. Patient 18 shows a mild phenotype that essentially contains the same, but less severe, clinical features. Patient 19 exhibits the typical, but very mild, dermatological and ocular abnormalities, without any clinical neurological involvement. The diagnosis of SLS was confirmed by demonstration of the enzyme defect in cultured skin fibroblasts. Furthermore, as might be predicted from the essential role of FALDH in leucotriene B4 (LTB4) metabolism, elevated urinary concentrations of LTB4 and 20-OH-LTB4 were found in all patients studied. Molecular studies of the FALDH gene revealed eight different mutations, including three new ones: a large 26-base pair deletion (21–46del), a missense mutation (80C
T) and an insertion mutation (487–488insA). The vast majority of SLS patients seem to be severely affected independent of their genotype.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R.-J. Sanders, R. Ofman, G. Dacremont, R. J. A. Wanders, and S. Kemp Characterization of the human {omega}-oxidation pathway for {omega}-hydroxy-very-long-chain fatty acids FASEB J, June 1, 2008; 22(6): 2064 - 2071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Elias, M. L. Williams, W. M. Holleran, Y. J. Jiang, and M. Schmuth Thematic review series: Skin Lipids. Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism J. Lipid Res., April 1, 2008; 49(4): 697 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. K. Westin, M. C. Hunt, and S. E. H. Alexson Peroxisomes Contain a Specific Phytanoyl-CoA/Pristanoyl-CoA Thioesterase Acting as a Novel Auxiliary Enzyme in {alpha}- and beta-Oxidation of Methyl-branched Fatty Acids in Mouse J. Biol. Chem., September 14, 2007; 282(37): 26707 - 26716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Marchitti, R. A. Deitrich, and V. Vasiliou Neurotoxicity and Metabolism of the Catecholamine-Derived 3,4-Dihydroxyphenylacetaldehyde and 3,4-Dihydroxyphenylglycolaldehyde: The Role of Aldehyde Dehydrogenase Pharmacol. Rev., June 1, 2007; 59(2): 125 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lossos, M. Khoury, W. B. Rizzo, J. M. Gomori, E. Banin, A. Zlotogorski, S. Jaber, O. Abramsky, Z. Argov, and H. Rosenmann Phenotypic Variability Among Adult Siblings With Sjogren-Larsson Syndrome Arch Neurol, February 1, 2006; 63(2): 278 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. van den Brink, J. M. van Miert, and R. J.A. Wanders Assay for Sjogren-Larsson Syndrome Based on a Deficiency of Phytol Degradation Clin. Chem., January 1, 2005; 51(1): 240 - 242. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. A. P. Willemsen, M. van der Graaf, M. S. van der Knaap, A. Heerschap, P. H. M. F. van Domburg, F. J. M. Gabreels, and J. J. Rotteveel MR Imaging and Proton MR Spectroscopic Studies in Sjogren-Larsson Syndrome: Characterization of the Leukoencephalopathy AJNR Am. J. Neuroradiol., April 1, 2004; 25(4): 649 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Hoon JR, K. M. Belsito, and L. M. Nagae-Poetscher Neuroimaging in Spasticity and Movement Disorders J Child Neurol, January 1, 2003; 18(1_suppl): S25 - S39. [Abstract] [PDF]
|
|